Skip to main content

Table 1 General characteristics on admission

From: Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium

Characteristics Value
Median age (range), y  
Adult (n = 65) 46.9 (18.4 - 83.6)
Child (n = 3) 4.8 (2.8 - 5.2)
Men, n (%) 47 (69)
Continent of birth, n (%)  
Europe 34 (50)
Africa 27 (40)
Other 7 (10)
Immunity status*, n (%)  
Non-immune 39 (57)
Partially immune 29 (43)
Semi immune 0 (0)
Chemoprophylaxis, n (%)  
Adequate 1 (2)
Inadequate 58 (85)
   Absent 49 (72)
   Inappropriate 9 (13)
Unknown 9 (13)
Indication for artesunate, n (%)  
Severe malaria§ (> 1 of the following criteria) 51 (75)
Impaired consciousness 18 (26)
Multiple convulsions (> 2 episodes/24 h) 0 (0)
Respiratory distress or pulmonary edema 4 (6)
Shock (systolic blood pressure < 70 mm Hg) 6 (9)
Haemoglobinuria 2 (3)
Abnormal bleeding 1 (2)
Hypoglycaemia (glucose < 2.2. mmol/L) 1 (2)
Acidaemia (pH < 7.25) 3 (4)
Acidosis (plasma bicarbonate < 15 mmol/L) 4 (6)
Anaemia (Hb < 3.1 mmol/l or haematocrit < 15%) 0 (0)
Hyperparasitaemia (> 5%) 33 (49)
Hyperlactataemia (lactate > 5 mmol/L) 8 (12)
Renal impairment (creatinine > 265 μmol/L) 7 (11)
Jaundice (bilirubin > 50 μmol/L) 24 (35)
Non severe malaria on admission 17 (25)
Clinical deterioration to severe malaria 4 (6)
Parasitaemia between 2-5% 4 (6)
Unable to take oral medication 5 (7)
Other 4 (6)
  1. * estimated as described earlier by Van Genderen et al. 2010 [11] Non-immune: European travellers and tourists; partially immune: adult immigrants from a malaria endemic country living in the Benelux; semi-immune: patients who had been living in a malaria-endemic area for at least 2 years preceding the time of diagnosis
  2. § One patient was diagnosed with a mixed infection of P.falciparum and P. malariae
  3. One patient was diagnosed with P.ovale, one with P. vivax
  4. One patient was diagnosed with P. vivax